报价延迟最少15分钟:2025/09/12 18:25 EDT
盘后时段
|
||||
|
17.43 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.39
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.68/2.48
|
|
企业价值
3.20B
|
| 资产负债 |
|
每股账面净值
12.97
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
301.03M
|
|
每股收益
10.56
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/12 18:25 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development. |
